



For settlement questions, or to get the claim process started, contact Janice Hart at (800) 729-5998 or email jhart@nationalequity.com

If you Bought or provided reimbursement for the Anticoagulant Medications Lovenox or Generic Enoxaparin you may be entitled to a substantial payment resulting from a class action settlement.

In re Enoxaparin Antitrust Settlement Case No. 15-cv-01100

Settlement Fund: \$120,000,000.00

Period of Claim: September 21, 2011 – September 30, 2015

Filing Deadline: September 1, 2020

Summary: A proposed settlement has been reached in a class action lawsuit regarding the price that uninsured consumers, hospitals, and third-party payors paid for Lovenox or generic enoxaparin. The lawsuit asserts that Defendants kept the prices of Lovenox and generic enoxaparin higher than they otherwise would have been by manipulating the generic approval process.

Eligibility: You may be a Class Member if you are a hospital, third-party payor, or a person without insurance who indirectly purchased, paid for, and/or reimbursed some or all of the purchase price for Lovenox or generic enoxaparin; **States included are: Arizona, Arkansas, California, District of Columbia, Florida, Hawaii, Illinois, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, South Dakota, Tennessee, Utah, Vermont, West Virginia, and Wisconsin.**

National Equity is not a law firm. If you require legal advice, please consult your attorney. The Court authorized website is: dvtmedslawsuit.com